Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
About this study
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
- Condition
- Lung Cancer
- Sponsor
- Samsung Medical Center
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Lung Cancer
- aged above or equal to 18
- Histologically confirmed lung cancer patients
- Patient treated with immune checkpoint inhibitor
- Exculsion Criteria:
Where
3 sites, 3 recruiting
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
Seoul National University Hospital
Seoul, Joungro-gu, South Korea
Asan Medical Center
Seoul, Songpa-gu, South Korea
Contact
-
Se-hoon Lee, MD
+82-10-4759-7640 sehoon.lee@samsung.com
-
Jinhee Seo
+82-70-7014-4158 rufina.seo@samsung.com
Potential match only. Final eligibility is determined by the study team.